Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

DexCom Inc

DXCM
Current price
69.96 USD +0.96 USD (+1.39%)
Last closed 68.61 USD
ISIN US2521311074
Sector Healthcare
Industry Medical Devices
Exchange NASDAQ
Capitalization 27 224 471 552 USD
Yield for 12 month -24.29 %
1Y
3Y
5Y
10Y
15Y
DXCM
21.11.2021 - 28.11.2021

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California. Address: 6340 Sequence Drive, San Diego, CA, United States, 92121

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

96.33 USD

P/E ratio

42.2424

Dividend Yield

Current Year

+3 622 300 000 USD

Last Year

+2 909 800 000 USD

Current Quarter

+994 200 000 USD

Last Quarter

+1 004 300 000 USD

Current Year

+2 288 900 000 USD

Last Year

+1 883 100 000 USD

Current Quarter

+593 800 000 USD

Last Quarter

+626 700 000 USD

Key Figures DXCM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 840 400 000 USD
Operating Margin TTM 15.29 %
PE Ratio 42.2424
Return On Assets TTM 6.06 %
PEG Ratio 1.1
Return On Equity TTM 32.06 %
Wall Street Target Price 96.33 USD
Revenue TTM 3 953 999 872 USD
Book Value 5.07 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 2 %
Dividend Yield
Gross Profit TTM 1 883 100 000 USD
Earnings per share 1.65 USD
Diluted Eps TTM 1.65 USD
Most Recent Quarter III 2024
Quarterly Earnings Growth YOY 15.7 %
Profit Margin 17.22 %

Dividend Analytics DXCM

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History DXCM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 4:1
Payout Ratio
Last Split Date 13.06.2022
Dividend Date

Stock Valuation DXCM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 42.2424
Forward PE 34.2466
Enterprise Value Revenue 6.9745
Price Sales TTM 6.9495
Enterprise Value EBITDA 28.2757
Price Book MRQ 13.885

Financials DXCM

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators DXCM

For 52 weeks

62.34 USD 142 USD
50 Day MA 69.94 USD
Shares Short Prior Month 9 554 763
200 Day MA 105.33 USD
Short Ratio 1.83
Shares Short 7 684 165
Short Percent 2.23 %